Theriva Biologics, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven A. Shallcross
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9605 Medical Center Drive Rockville MD United States of America 20850
- IPO Date
- Dec 18, 2006
- CIK
- 0000894158
- Website
- therivabio.com
- Similar Companies
- Business
- Theriva Biologics, Inc. Theriva Biologics, Inc. (NYSE American: TOVX) is a diversified clinical-stage biopharmaceutical company developing oncolytic virus therapeutics and microbiome-protecting agents to treat cancer and related diseases in areas of high unmet medical need. The company offers VCN-01 (zabilugene almadenorepvec), an intravenously administered oncolytic adenovirus engineered to selectively replicate in tumor cells, degrade tumor stroma barriers, enhance co-administered chemotherapy and immunotherapy access, and stimulate anti-tumor immune responses; VCN-11, a preclinical oncolytic virus leveraging proprietary Albumin Shield Technology for systemic protection against host immunity; SYN-004 (ribaxamase), an oral enzyme designed to degrade intravenous beta-lactam antibiotics in the gastrointestinal tract, thereby preventing microbiome damage, pathogenic overgrowth such as vancomycin-resistant Enterococci, Clostridioides difficile infection, and acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase intended for local gastrointestinal and systemic disease treatment. Theriva Biologics operates through its wholly owned subsidiary Theriva Biologics, S.L. in Rockville, Maryland, with headquarters in the United States and research activities spanning Spain and the USA; the company, formerly Synthetic Biologics, rebranded in 2022 following the acquisition of VCN Biosciences and traces its immuno-oncology focus to advancements in oncolytic adenovirus platforms since that time. In 2025, Theriva Biologics completed a $7.5 million public offering of common stock and warrants to fund research, development, manufacturing scale-up, working capital, and potential strategic investments or acquisitions, and announced a warrant inducement transaction expected to generate $4.0 million in gross proceeds upon closing in October 2025.
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2025
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell?
Why Is Theriva Biologics Stock Gaining Monday?
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Theriva Biologics (NYSEAMERICAN:TOVX) Trading 5.2% Higher – Here’s Why
Theriva Biologics (NYSEAMERICAN:TOVX) Trading 3.4% Higher – Still a Buy?
Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Grows By 61.7%
Theriva Biologics Provides Response to Unusual Market Action
Theriva™ Biologics anuncia una operación de incentivo de warrants por un importe bruto de 4 millones de dólares
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results